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Case Report

Primary lung carcinoid metastatic to the breast
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abstract
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Lung carcinoid tumors account for approximately 2% of lung cancers, with 10% of the
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tumors represented by the atypical type. While atypical carcinoids are metastatic to
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intrathoracic lymph nodes in approximately half of the cases on the initial presentation,
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distant metastases are seen in only 20% of the patients and are found most frequently in
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bones, liver, adrenal glands, and brain. We present a case of an unusual metastatic disease
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to the breast in 51-year-old female who developed a new breast mass 2 years after left
lower lobectomy due to atypical carcinoid tumor. Atypical pulmonary carcinoid metastases
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to the breast are exceptionally uncommon, yet they are important considerations for
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appropriate management, especially with an anamnesis of this neoplasm.
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Introduction
Pulmonary neuroendocrine tumors arise from Kulchitsky
cells that are found in the bronchial mucosa and responsible
for production and storage of neuroendocrine peptides [1].
Pathologic proliferation of these cells can lead to formation of
small tumorlets, low- and intermediate-grade neoplasms, or
more aggressive tumors [1]. The biological behavior of these
proliferated cells reflects their histologic aggressiveness and
ranges from asymptomatic lesions to nefarious malignancies
such as small cell lung cancer and large cell neuroendocrine
tumors with 5-year survival rate of 21% [2]. Typical carcinoid
tumors represent low-grade lung neuroendocrine neoplasms,
accounting for 90% of all carcinoid lung tumors [3]. These

tumors usually present as an incidentally discovered or
symptomatic noncalcified or partially calcified solid peribronchial or partially or completely obstructing endobronchial lesion in a young individual [4]. The 5-year survival rate
is approximately 97%, and the metastatic potential is low: 5%e
15% to intrathoracic lymph nodes and only 3% to distant sites
[3]. Conversely, atypical carcinoids are considered intermediate neoplasms and account for 10%e20% of bronchopulmonary neuroendocrine tumors [3]. Atypical carcinoids are much
more likely to have systemic manifestations and significantly
lower 5-year survival rate of 57% [3]; 40%e50% of patients
present initially with metastases to intrathoracic lymph
nodes, and approximately 20% have distant disease [3]. Both
typical and atypical carcinoids occasionally can present with
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Fig. 1 e Axial chest CT in lung (A) and mediastinal (B) windows shows a medial left lower lobe 2.1 cm nodule (arrows) that
abuts and narrows the lobar bronchus. Intraoperatively, bronchial invasion was confirmed.

multifocal deposition of tumorlets along peripheral airways,
which may be due to metastatic disease or diffuse idiopathic
pulmonary neuroendocrine cell hyperplasia (DIPNECH) [5].
Patients with DIPNECH are typically present with symptoms
of reactive small airways disease and frequently undergo
multiregimen treatment for asthma without improvement [1].
Here, we present a case of a patient with an initial diagnosis of left lower atypical carcinoid and concomitant DIPNECH discovered during workup of chronic cough.
Subsequent metastases to the brain and left breast were found
after 2 years in remission.

neuroendocrine differentiation) and negative for GATA3
immunostain (marker of primary breast malignancy) [1].
During further metastatic workup, contrasted MRI of the brain
demonstrated several focal lesions with biopsy results of
neuroendocrine cell metastases as well (Figs. 10A and B).
The patient had since completed whole-brain radiation
therapy for metastatic carcinoid tumor to the brain. She then
initiated everolimus every other day for her persistent cough.
A slowly growing small nodule was noted in the left upper
lobe on follow-up CT chest representing either progression of
metastatic tumorlets or worsening concomitant DIPNECH
(Fig. 11).

Case report
The patient is a 51-year-old Caucasian female who presented
to the pulmonology service with a chronic cough interfering
with daily activities. She was referred to pulmonology after
numerous years of multiple unsuccessful treatment trials for
reactive small airways disease. Upon further workup, CT chest
demonstrated medially located 2.1 cm left lower lobe solitary
pulmonary nodule, closely abutting and narrowing left lower
lobar bronchus (Figs. 1A and B). Subsequent FDG-PET/CT
demonstrated significant hypermetabolic activity of the
lesion (Fig. 2). The patient underwent bronchoscopy with biopsy with final tissue diagnosis of a neuroendocrine tumor
consistent with well-differentiated carcinoid. Intraoperative
histopathologic assessment reported staging as pT3N1, with
evidence of invasion of the left lower lobar bronchus, the
adjacent left inferior pulmonary vein, and a lymph node just
medial to the bronchus. Some residual neoplastic tissue was
found at the surgical stump, necessitating long-term monthly
Sandostatin injections following left lower lobectomy and
partial mediastinal lymph node dissection.
Two years later, a routine screening mammogram revealed
a new 7-mm indistinct mass (Figs. 3A and B) in the left breast.
Subsequent workup with diagnostic mammography and
breast ultrasound (Figs. 4A and B and Figs. 5A and B) confirmed
the lesion as highly suspicious. Intraoperative histopathologic
analysis and special immunostains of the lesion (Figs. 6e9)
revealed a neuroendocrine cell origin with positive stains for
synaptophysin
and
chromogranin
(markers
of

Discussion
Atypical carcinoids are categorized as intermediate-grade
malignancies, with the designation as atypical carcinoid
being based on moderate cytological atypia, necrosis, mitotic

Fig. 2 e FDG-PET/CT shows significant hypermetabolic
activity of left lower lobe nodule with a maximum SUV of 8.0.
Notice the close relationship to the left inferior pulmonary
vein that was found to be invaded in intraoperative
examination. FDG-PET/CT, fluorodeoxyglucose positron
emission tomography/computed tomography; SUV,
standardized uptake value.
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Fig. 3 e (A) Screening mammogram left CC image reveals a new oval mass (arrow) measuring 7 mm in the posterior third of
the left breast at the 12:00 position, 10 cm from the nipple. (B) Enlarged left CC tomosynthesis view of the new mass shows
an indistinct, angular margin. CC, craniocaudal.

Fig. 4 e (A) Screening mammogram left MLO image reveals a new oval mass (arrow) measuring 5 mm in the posterior third
of the left breast at the 12:00 position, 10 cm from the nipple. (B) Enlarged left MLO tomosynthesis image showing the new,
irregular mass. MLO, mediolateral oblique.
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Fig. 5 e Ultrasound performed after initial screening mammogram demonstrates a hypoechoic mass with indistinct
margins (A), parallel orientation, without internal vascularity (B), nor posterior acoustic shadowing or enhancement.

activity (greater than 2 but less than 10 cells per high power
field), and higher metastatic and invasive potential [6]. Much
lower 5-year survival rates are generally present than with
overwhelmingly indolent typical carcinoids [6]. Our patient
suffered not only from an atypical carcinoid, but concomitant
systemic manifestation known as DIPNECH with chronic refractory cough.
DIPNECH was originally described in 1992, when lung
surgical pathology specimens revealed neuroendocrine cell
hyperplasia surrounding carcinoid foci in patients presenting
with small airways disease [5]. Both DIPNECH and carcinoid
tumors can present with small multifocal tumorlets [1].
Mosaic attenuation due to air trapping and small scattered
solid or groundglass nodules with or without bronchial wall
thickening on high-resolution CT chest is classic findings in
one-third of symptomatic patients with DIPNECH [1]. Another
half of patients with neuroendocrine cell hyperplasia are
asymptomatic, with nodules incidentally discovered for other
reasons [1]. Frequent coexistence of carcinoid tumor(s) and

nodules from DIPNECH is commonly reported on pathology
reports [5]. Symptoms due to DIPNECH resemble refractory
asthma and result from constrictive bronchiolitis due to proliferation of neuroendocrine cells along distal airways, leading
to intramural and extramural fibrosis [1]. Affected individuals
with DIPNECH are almost exclusively middle-aged and older
women [5]. It is still unknown why disease manifestation
preferentially selects this specific demographic group. On a
cellular level, DIPNECH occurs from the pulmonary neuroendocrine cell production of bombesin and gastrin releasing
peptide [5]. These ligands kindle exorbitant fibroblastic reaction which induces bronchoconstriction, chemotaxis of other
inflammatory cells, and ultimately interstitial fibrosis [5].
Distinction from hypersensitivity pneumonitis or obstructive
bronchiolitis can be difficult without clinical insight, since all
induce marked endobronchial inflammation [1].
Metastatic atypical pulmonary carcinoid to the breast is
exceptionally uncommon, with only 13 reported cases in the
English literature. It is generally unknown why breast

Fig. 6 e Left breast lesion at 12:00, 7 cm from nipple,
ultrasound-guided core needle biopsy. Pathology revealed
a well-differentiated neuroendocrine tumor. Normal breast
tissue (blue arrow) and a well-differentiated
neuroendocrine tumor (red arrow) were noted.

Fig. 7 e The tumor is vascular, with cells arranged in a
trabecular and nested pattern. The cells have scant to
moderate amounts of cytoplasm with round nuclei and no
nucleoli. No atypia, necrosis, or mitoses are present. No
normal breast tissue is shown on this image.
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Fig. 8 e Tumor cells are positive for chromogranin (shown),
synaptophysin, and CD56 which are markers of
neuroendocrine differentiation.

metastases are so infrequent; however, it is postulated that
since survival time interval is relatively constricted, many
cases go unreported. The histopathologic and immunohistochemical distinction is crucial for distinguishing metastatic
neuroendocrine neoplasm to the breast from invasive mammary carcinoma as appropriate clinical management can
differ. Histologically, nearly all metastatic neuroendocrine
tumors to the breast are strongly and diffusely positive for
neuroendocrine markers, synaptophysin and chromogranin
[7]. In addition, a neuroendocrine metastasis will be estrogen
receptor negative and GATA3 negative. Breast neuroendocrine
metastasis from a lung primary is commonly thyroid transcription factor-1 positive, as opposed to negative in a primary
breast carcinoma [7]. The median survival for metastatic
atypical pulmonary carcinoid is 3.3 years, with a 5-year
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Fig. 9 e The tumor cells were negative for GATA-3 which is
a breast marker. Only nonspecific bluish background
staining is noted. This finding argues against a primary
breast lesion.

survival rate at a dismal 24% [6]. However, newer treatment
therapies have shown promise. Newer treatment therapies
primarily consist of chemotherapeutic agents such as adjuvant platinumeetoposide chemoradiation, temozolomidebased therapies, and octreotide-based therapy, for those
with octreotide avid disease [6]. Results are promising, with
10% treatment response, and 70% nonprogression in patients
receiving octreotide-based therapies [6]. The average patient
treated with this regimen remained stable for a median time
of 15 months [6]. For patients with nonoctreotide avid disease,
adjuvant
platinumeetoposide
chemoradiation
and
temozolomide-based therapies also have had promising rates

Fig. 10 e Axial T1 postcontrast image (A) shows metastatic disease with an 17 £ 16 mm enhancing dural-based lesion in the
peripheral left frontal lobe and an additional 6-mm lesion in the right cerebellum (B).
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a new breast mass in a patient with prior history of invasive
carcinoid tumor. Current established histopathologic immunostain analysis would aid to definite diagnosis and timely
management.
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references
of treatment response and disease nonprogression. These
patients on average experience a median time of 7 and 10
months of progression-free disease, respectively [6]. Because
these tumors are so rare, there is no clear recommendation for
surgical management. Historically, patients with breast metastases typically underwent mastectomy because the lesion
was often incorrectly diagnosed as a primary carcinoma [8]. In
a patient with a few metastatic lesions that are amenable to
resection, lumpectomy alone would be acceptable [8]. Axillary
lymph node dissection would only be necessary if there was
palpable lymphadenopathy [8].

Conclusion
Atypical carcinoid with concomitant DIPNECH is not common.
Furthermore, metastasis to the breast is exceptionally infrequent with only a few reported cases in the modern literature.
In the past, metastatic atypical carcinoid has shown a meager
5-year survival rate. However, newer treatment modalities are
offering hope to those suffering from this disease. Although
rare, this case report demonstrates the importance of
considering metastatic disease in the differential diagnosis for
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